Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure Post author: Post published:September 3, 2024 Post category:uncategorized MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients. You Might Also Like 2023 Michigan Nurses Study reveals improved conditions, but burnout and abuse persist July 18, 2024 Study highlights growing burden of neurological disorders worldwide March 16, 2024 Food allergies may be linked to increased cardiovascular death risk, study finds November 13, 2023